Meihua International Medical Technologies Co., Ltd. Received Nasdaq Delisting Notice

Rhea-AI Summary

Meihua International Medical Technologies (Nasdaq: MHUA) received a Nasdaq delisting notice on December 2, 2025, after Nasdaq determined the company did not regain compliance with Listing Rule 5550(a)(2).

Nasdaq previously notified Meihua of a bid-price deficiency on December 3, 2024 and provided compliance periods ending June 2, 2025 and December 1, 2025. Meihua completed a 1:16 reverse share split on November 24, 2025 but did not maintain a $1.00 minimum bid for the required period. Trading is scheduled to be suspended at the opening on December 9, 2025. The company submitted a hearing request on December 4, 2025. Nasdaq also found Meihua had fewer than 500,000 publicly held shares as of December 1, 2025, a separate basis for delisting.

Positive

• Reverse share split executed at 1:16 on November 24, 2025
• Company filed a hearing request on December 4, 2025 to appeal the delisting

Negative

• Nasdaq determined to delist MHUA for noncompliance with Listing Rule 5550(a)(2)
• Trading to be suspended at market open on December 9, 2025
• Failed to meet the $1.00 minimum bid requirement before December 1, 2025
• Held fewer than 500,000 publicly held shares as of December 1, 2025 (Rule 5550(a)(4) noncompliance)

Key Figures

Minimum bid price $1.00 per share Nasdaq Listing Rule 5550(a)(2) requirement

Initial compliance period 180 calendar days Period to regain $1 bid price compliance to June 2, 2025

Second compliance period 180 calendar days Extended to demonstrate compliance by December 1, 2025

Reverse split ratio 1:16 Reverse share split effective November 24, 2025

Public float requirement 500,000 publicly held shares Nasdaq Listing Rule 5550(a)(4) minimum

Public float shortfall Less than 500,000 shares Publicly held shares as of December 1, 2025

Trading suspension date December 9, 2025 Scheduled suspension of ordinary share trading

Appeal request date December 4, 2025 Date company submitted appeal of delisting determination

Market Reality Check

$12.89 Last Close

Volume Volume 8,584 is below 20-day average 11,369 (relative volume 0.76). normal

Technical Price 12.89 is trading below 200-day MA at 35.06, reflecting prior downtrend.

Peers on Argus

Peers in Healthcare/Medical Instruments showed mixed moves, with gains in FEMY and LUCY but declines in EKSO and modest changes in HBIO and RVP, pointing to stock-specific factors for MHUA.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 19	Reverse share split	Neutral	+1.7%	Announced 1-for-100 reverse split and dual-class share structure change.

Pattern Detected

Recent corporate actions centered on capital structure changes, with only a modest price reaction.

Recent Company History

Over the past few weeks, MHUA focused on capital structure adjustments. A 1-for-100 reverse share split effective November 24, 2025 reduced Class A shares from about 56 million to about 0.56 million, with the stock rising about 1.72% over the next day. Today’s Nasdaq delisting notice adds a separate compliance setback, shifting attention from structural cleanup to listing-status risk.

Market Pulse Summary

The stock is dropping -25.7% following this news. A negative reaction despite the stock having risen 10.93% before this announcement would fit a shift from prior neutral responses to capital actions toward clear concern over listing risk. The notice cites failure to meet the $1.00 bid requirement and having fewer than 500,000 publicly held shares, with trading suspension scheduled for December 9, 2025. These dual compliance issues could justify heightened downside pressure.

Key Terms

nasdaq capital market regulatory

"to delist the Company’s ordinary shares from The Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

listing rule 5550(a)(2) regulatory

"failed to regain compliance with the Nasdaq Listing Rule 5550(a)(2)"

Listing Rule 5550(a)(2) is a Nasdaq listing standard that sets a minimum share-price requirement for securities to be listed or to remain listed on the Nasdaq Capital Market. It matters to investors because falling below that minimum can trigger delisting reviews or increased volatility, much like a safety bar on a ride — if a stock can’t meet the height requirement, it risks being removed from the exchange, which can reduce liquidity and access for buyers and sellers.

reverse share split financial

"The Company effectuated a reverse share split of its ordinary shares"

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

publicly held shares regulatory

"which requires Nasdaq listed companies to have at least 500,000 publicly held shares"

Shares that are publicly held are portions of a company that any investor can buy or sell on public markets, like slices of a pie owned by many people rather than a few insiders. They matter because they determine how easy it is to trade the stock, influence company control through voting and can affect price swings and dividend payments as supply and demand change in the market.

AI-generated analysis. Not financial advice.

Yangzhou, China, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Meihua International Medical Technologies Co., Ltd. (“Meihua” or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, announced today that the Company received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) on December 2, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company’s ordinary shares from The Nasdaq Capital Market (the “Delisting Determination”), because the Company failed to regain compliance with the Nasdaq Listing Rule 5550(a)(2) (the “Rule”).

As previously disclosed, on December 3, 2024, the Nasdaq staff notified the Company that the bid price of its listed ordinary shares had closed at less than $1 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until June 2, 2025, to regain compliance with the Rule. Subsequently, on June 6, 2025, the Company transferred to The Nasdaq Capital Market and it was afforded the remainder of the second 180-calendar-day compliance period, or until December 1, 2025, to demonstrate compliance.

The Company effectuated a reverse share split of its ordinary shares at the ratio of 1:16 on November 24, 2025, but failed to meet the $1.00 minimum bid price requirement for at least 10 consecutive business days before December 1, 2025. The trading of the Company’s ordinary shares will be suspended at the opening of business on December 9, 2025.

The Company was provided until December 9, 2025 to request an appeal of the Delisting Determination to the hearing panel. The Company submitted the hearing request on December 4, 2025.

Additionally, on December 1, 2025, the Nasdaq Staff notified the Company that it no longer complies with Listing Rule 5550(a)(4), which requires Nasdaq listed companies to have at least 500,000 publicly held shares. As of December 1, 2025, the Company has less than 500,000 publicly held shares, thus failed to meet the Nasdaq requirement. This matter serves as an additional and separate basis for delisting.

About Meihua International Medical Technologies Co., Ltd.

Meihua International Medical Technologies Co., Ltd. is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strips, and anal bags, and Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under the Company's own brands and are also sourced and distributed from other manufacturers. The Company has received an international "CE" certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for over 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for more than 30 years, providing over 1,000 types of products for domestic sales, as well as over 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania.

For more information, please visit www.meihuamed.com.

Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua. 

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact in this press release are forward-looking statements, including but not limited to, the use of proceeds from the Company's offering, the intent, belief or current expectations of Top KingWin and members of its management, as well as the assumptions on which such statements are based. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the SEC.

For further information, please contact.

IR Department
Email: secretary@meihuamed.com
Tel: +86-0514-89800199

FAQ

Why did Nasdaq issue a delisting notice for Meihua (MHUA) on December 2, 2025?

Nasdaq determined Meihua failed to regain compliance with Listing Rule 5550(a)(2) after prior bid-price noncompliance and additional share-count noncompliance.

When will MHUA trading be suspended on Nasdaq?

Trading is scheduled to be suspended at the opening of business on December 9, 2025.

Did Meihua take any corporate actions to regain compliance before the delisting?

Yes. The company completed a 1:16 reverse share split on November 24, 2025 but still failed to meet the $1.00 minimum bid requirement.

Has Meihua appealed the Nasdaq delisting determination for MHUA?

Yes. Meihua submitted a hearing request on December 4, 2025 to appeal the delisting determination.

What additional Nasdaq rule did Meihua fail to satisfy as of December 1, 2025?

As of December 1, 2025, Meihua had fewer than 500,000 publicly held shares, failing Listing Rule 5550(a)(4).

What immediate effect does the delisting notice have for MHUA shareholders?

Nasdaq has determined to delist and set a December 9, 2025 suspension date; shareholders should monitor the appeal and any company updates.